Abstract 206P
Background
To compare discriminant ability of risk stratifications for prostate cancer in three authoritative guidelines: National Comprehensive Cancer Network clinical practice guideline (NCCN-g), American Urological Association / American Society for Therapeutic Radiology and Oncology/ Society of Urologic Oncology Guideline(AUA-g) and European Association of Urology- European association of nuclear medicine- European Society for Radiotherapy and Oncology- European Society of Urogenital Radiology- International Society of Geriatric Oncology guideline(EAU-g).
Methods
511916 patients with one primary prostate cancer diagnosed between 2004 and 2016 were identified using the Surveillance, Epidemiology, and End Results (SEER, submitted in) database of the National Cancer Institute. Patients were excluded from analysis if < 18 years of age, not adenocarcinoma, diagnosed at autopsy or death certificate only, with an unknown follow-up, incomplete clinical and demographic information, leaving 287333 patients in this cohort. Patients were categorized as different risk stratifications by three latest guidelines (NCCN-g, AUA-g and EAU-g) respectively. Follow-up endpoint was prostate cancer specific mortality (PCSM), cutoff date was December 31, 2016. Kaplan–Meier analysis, multivariable Cox regression and area under the receiver operating characteristics (ROC) curve (AUC) analyses were performed.
Results
The 287333 patients are all from 2004 to 2015. Median follow-up was 69 months (IQR: 39-104). For the three risk stratification modalities, all 6 risk groups in NCCN-g, 5 risk groups in AUA-g and 5 risk groups in EAU-g independently predicted PCSM. NCCN-g yielded 3.1-fold HR differences between low risk group and intermediate risk group, 14.8-fold HR differences between low risk group and high risk group, 33.0-fold HR differences between low risk group and very high risk group, 56.2-fold HR differences between low risk group and regional group, and 148.9-fold HR differences between low risk group and metastatic group. AUC is 0.8332, 0.8309 and 0.7868 in NCCN-g, AUA-g and EAU-g.
Conclusions
This large population-based analysis confirms the better discriminant properties of the risk stratification method in NCCN guideline.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Peking University First Hospital radiation oncology department.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
238P - Laparoscopic cytoreduction in low disease burden, advanced-stage ovarian cancers: Experience from a tertiary cancer center
Presenter: Vikas Gupta
Session: Poster display session
Resources:
Abstract
239P - Impact of counseling on patient reported sexual adjustment following chemoradiation and brachytherapy for cervical cancer
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
240P - Morbidity and mortality of cervical cancer in the Republic of Kazakhstan
Presenter: Almagul Zhabagina
Session: Poster display session
Resources:
Abstract
241P - Impact of genomic alterations and HPV genotypes on clinical outcomes of Japanese patients with locally advanced cervical cancer
Presenter: Ikumi Kuno
Session: Poster display session
Resources:
Abstract
242P - Impact of combined interstitial and intracavitary brachytherapy in locally advanced cervical cancer: A survival and toxicity profile assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
243P - Cervical cancer screening in sub-urban area of Banten and factor associated with uptake of screening
Presenter: Prio Wibisono
Session: Poster display session
Resources:
Abstract
245P - Factors influencing adherence to cryotherapy following positive VIA result as cervical cancer prevention in Temanggung, Central Java, Indonesia
Presenter: Herindita Puspitaningtyas
Session: Poster display session
Resources:
Abstract
246P - The main of reasons of advanced stage cervical cancer in Uzbekistan
Presenter: Zakhirova Nargiza
Session: Poster display session
Resources:
Abstract
247P - Role of ADC values in assessing response after chemoradiotherapy in cervix cancer and in identifying residual disease
Presenter: Venkata Pradeep Babu Koyyala
Session: Poster display session
Resources:
Abstract
248P - Retrospective review of metastatic carcinoma of cervix from a tertiary cancer institute of south India
Presenter: Arkoprovo Halder
Session: Poster display session
Resources:
Abstract